rs199935023
Variant summary
Our verdict is Pathogenic. The variant received 10 ACMG points: 10P and 0B. PM1PP5_Very_Strong
The NM_003560.4(PLA2G6):c.991G>T(p.Asp331Tyr) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000148 in 1,557,154 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. D331N) has been classified as Uncertain significance.
Frequency
Consequence
NM_003560.4 missense
Scores
Clinical Significance
Conservation
Publications
- neurodegeneration with brain iron accumulation 2AInheritance: AR Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: G2P, Ambry Genetics, Genomics England PanelApp, Orphanet, Labcorp Genetics (formerly Invitae)
- neurodegeneration with brain iron accumulation 2BInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
- PLA2G6-associated neurodegenerationInheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
- autosomal recessive Parkinson disease 14Inheritance: AR Classification: STRONG, MODERATE, SUPPORTIVE Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 10 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152258Hom.: 0 Cov.: 33 show subpopulations
GnomAD2 exomes AF: 0.0000486 AC: 8AN: 164594 AF XY: 0.0000229 show subpopulations
GnomAD4 exome AF: 0.0000135 AC: 19AN: 1404778Hom.: 0 Cov.: 31 AF XY: 0.0000101 AC XY: 7AN XY: 693754 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152376Hom.: 0 Cov.: 33 AF XY: 0.0000268 AC XY: 2AN XY: 74512 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not provided Pathogenic:2
PLA2G6: PM3:Very Strong, PM2, PS3:Supporting -
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 21700586, 25660576, 22213678, 29454663, 30302010, 31196701, 30772976, 31496990, 32183746, 30088174, 32961396) -
PLA2G6-associated neurodegeneration Pathogenic:2
The PLA2G6 c.991G>T; p.D331Y variant has been reported associated with parkinsonism (Shi 2011, Chu 2020, Liu 2022, Xie 2015). Furthermore, the functional studies have demonstrated that p.D331Y variant results in early-onset degeneration of Dopaminergic neurons (Chiu 2018, Ke 2020). This variant is associated with the following publications: PMID: 21700586, 32183746, 36150414, 25660576, 32071291, 30088174. -
The p.Asp331Tyr variant in PLA2G6 has been reported in at least 4 individuals with PLA2G6-associated neurodegeneration (PMID: 29454663, 31196701, 22213678) and has been identified in 0.08% (11/13680) of East Asian chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs199935023). Although this variant has been seen in the general population in a heterozygous state, its frequency is not high enough to rule out a pathogenic role. This variant has also been reported in ClinVar (Variation ID#: 30371) and has been interpreted as pathogenic by GeneDx and OMIM. Of the 4 affected individuals, 1 was a compound heterozygote that carried a reported likely pathogenic variants in trans and 2 of those were homozygotes, which increases the likelihood that the p.Asp331Tyr variant is pathogenic (Variant ID: 279875; PMID: 29454663, 31196701, 22213678). In vitro functional studies provide some evidence that the p.Asp331Tyr variant may slightly impact protein function (PMID: 21700586). However, these types of assays may not accurately represent biological function. Animal models in mice have shown that this variant causes PLA2G6-associated neurodegeneration (PMID: 30088174). Computational prediction tools and conservation analyses do not provide strong support for or against an impact to the protein. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive PLA2G6-associated neurodegeneration. ACMG/AMP Criteria applied: PM3_strong, PS3 (Richards 2015). -
Infantile neuroaxonal dystrophy;C1857747:Neurodegeneration with brain iron accumulation 2B;C2751842:Autosomal recessive Parkinson disease 14 Pathogenic:2
PM2_Supporting+PS3_Moderate+PM3_VeryStrong+PP4 -
- -
Infantile neuroaxonal dystrophy Pathogenic:1
This sequence change replaces aspartic acid, which is acidic and polar, with tyrosine, which is neutral and polar, at codon 331 of the PLA2G6 protein (p.Asp331Tyr). This variant is present in population databases (rs199935023, gnomAD 0.08%). This missense change has been observed in individual(s) with Parkinson disease (PMID: 21700586, 22213678, 25660576). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 30371). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt PLA2G6 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects PLA2G6 function (PMID: 21700586). For these reasons, this variant has been classified as Pathogenic. -
Autosomal recessive Parkinson disease 14 Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at